Skip to main content

Table 1 Overview of study time points, interventions and analyses

From: High-dimensional assessment of B-cell responses to quadrivalent meningococcal conjugate and plain polysaccharide vaccine

 

Study day 0

Study day 7

Study day 21

Study day 28

Study day 35

Study day 49

Study day 56

Group

 Group 1 (n = 5)

MenACWY-CRM (i/m)

  

MenACWY-CRM (i/m)

   

 Group 2 (n = 5)

MenACWY-PS (i/m)

  

MenACWY-CRM (i/m)

   

 Group 3 (n = 5)

MenACWY-PS (s/c)

  

MenACWY-CRM (i/m)

   

 Group 4 (n = 5)

MenACWY-PS (1/5 i/m)

  

MenACWY-CRM (i/m)

   

Immunological phenotypes

 SBA (MenA and MenC)

  

  

 B mem ELISpots (MenA, MenC, DT)

  

  

Systems tools

 Flow cytometry

 Transcriptomics

  

  
  1. i/m intramuscular, s/c subcutaneous, 1 / 5 a fifth of the standard dose was administered, SBA serum bactericidal assay, B mem ELISpots B-cell memory enzyme-linked immunospot, DT diphtheria toxoid